Zydus Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

The company said the Drug Controller General of India (DCGI) had earlier approved the manufacturing and marketing of the Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus Biotech Park in Ahmedabad. The company said the average monthly cost of therapy is expected to be around Rs 2,200.

Zydus also highlighted that diabetes and obesity are major public health challenges in India. Citing the International Diabetes Federation, it noted that 8.9 crore adults in India are living with diabetes, representing 10.5% of the adult population. The company further pointed out a sharp rise in obesity prevalence among adults, increasing by 91% in women and 146% in men, underscoring the growing burden of lifestyle-related diseases in the country.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The company?s consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE.

Powered by Capital Market - Live News

Zydus Lifesciences has launched Semaglutide Injection under the brand names ? SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. Zydus' Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.

Powered by Capital Market - Live News

Aerolife Mini is India?s first portable and foldable spacer, designed for convenience and ease of use. The device has been launched under an exclusive licensing agreement with AeroDel Technology Innovations.

According to the company, India faces a growing burden of chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis, driven by factors such as rising air pollution, smoking, recurrent infections, and delayed diagnosis. Millions of patients rely on long-term inhaled therapies to control symptoms and maintain quality of life.

While inhaled medications are central to treatment, effective delivery remains a challenge. Real-world studies indicate that nearly 94% of patients make at least one critical inhaler technique error, reducing drug efficacy. Spacer devices improve lung deposition by reducing coordination errors, but most existing products are bulky, difficult to transport, and require repeated assembly, limiting adherence.

Aerolife Mini? addresses these limitations with a compact, foldable, ready-to-use design, aiming to improve drug deposition, enhance compliance, boost patient confidence, and provide greater convenience.

This launch aligns with Zydus Lifesciences?s long-term strategy of building innovation-led, patient-centric respiratory franchises.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The company?s consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences fell 1.94% to Rs 888.45 on the BSE.

Powered by Capital Market - Live News

Zydus Lifesciences has launched Aerolife Mini?, a next-generation pMDI enhancer marking a significant step in the company's strategy to drive drug device led innovation that in respiratory care. Aerolife Mini? is India's first portable and foldable spacer, making it highly convenient to use. Zydus has launched this device under an exclusive licensing arrangement with AeroDel Technology Innovations.

Aerolife Mini? introduces a compact, foldable, and ready to use design that fundamentally redefines how spacers are used. The drug device is expected to achieve better drug deposition, improve compliance enhance patient confidence and provide greater convenience. 

Powered by Capital Market - Live News